ContributorsPublishersAdvertisers

Tremelimumab Plus Durvalumab Improves Survival in Frontline Unresectable HCC

onclive.com
 2021-10-15

A single, high priming dose of tremelimumab plus durvalumab resulted in a statistically significant and clinically meaningful improvement in overall survival vs sorafenib when used in the frontline treatment of patients with unresectable hepatocellular carcinoma who had not previously received systemic therapy and were not eligible for localized treatment....

www.onclive.com

Comments / 0

Comments / 0